Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. (NASDAQ: LTRN) generates a steady flow of news as an AI-driven, clinical-stage oncology company advancing both a precision medicine pipeline and a proprietary artificial intelligence platform. News coverage on this page centers on developments in its RADR® AI and machine learning platform, clinical trial milestones for LP-184, LP-284, and LP-300, regulatory interactions, and strategic initiatives that shape the company’s position in AI-enabled cancer drug development.
Investors and researchers following LTRN news will find detailed updates on Phase 1 and Phase 2 clinical trials, including safety and efficacy readouts, biomarker findings, and disease control observations in heavily pre-treated cancer patients. Recent announcements have highlighted LP-184’s Phase 1a results in advanced solid tumors, LP-284’s activity in relapsed or refractory B-cell lymphomas, and LP-300 data from the HARMONIC™ trial in never-smoker non-small cell lung cancer. Lantern also reports on FDA designations such as Fast Track, Orphan Drug, and Rare Pediatric Disease status that influence development pathways for its drug candidates.
In addition to clinical results, Lantern’s news stream covers the evolution of its RADR® platform and related AI modules. Articles describe the launch and performance of tools like predictBBB.ai for blood–brain barrier prediction and LBx-AI for liquid biopsy-based treatment response modeling, as well as presentations at scientific meetings and symposia. Corporate news items include quarterly financial updates, at-the-market financing agreements, board appointments, proxy statements, and the announcement of an AI Center of Excellence in Bengaluru, India to scale RADR® and multi-agent AI systems for global biopharma partners.
By reviewing the LTRN news feed, readers can track how Lantern integrates AI, genomics, and clinical data into its oncology programs, how regulators and collaborators engage with its pipeline, and how the company positions its AI modules and partnerships in the broader biopharmaceutical landscape. This page is a resource for monitoring material events, clinical inflection points, and platform advances that Lantern discloses through press releases and regulatory communications.
Lantern Pharma (LTRN) announced that its RADR® A.I. platform has surpassed 10.4 billion datapoints, enhancing its capabilities in oncology drug discovery. This integrated platform offers mechanistic insights into drug-tumor interactions, optimizing drug development strategies and accelerating the identification of effective cancer therapies. Key advancements include new data sources from glioblastoma and pancreatic cancer, alongside improved algorithms to analyze complex datasets quickly. Lantern aims to leverage RADR® for innovative drug-candidate discoveries, ultimately seeking to improve clinical outcomes for cancer patients.
Lantern Pharma (LTRN) announced a collaboration with Code Ocean to enhance its oncology drug discovery efforts using AI. This partnership aims to leverage Code Ocean's Compute Capsule technology to improve the RADR® platform, making research more efficient. The integration focuses on data analysis, collaboration, and reproducibility, potentially reducing costs and development timelines. Lantern Pharma utilizes machine learning to develop therapeutics, currently working on four drug candidates. The collaboration supports partnerships with notable research institutions, optimizing research workflows and productivity.
Code Ocean has partnered with Lantern Pharma (LTRN) to enhance AI-driven computational research for oncology drug discovery. Leveraging Code Ocean's Compute Capsule technology, this collaboration aims to improve efficiency in development time and costs while increasing reproducibility. The integration will help Lantern Pharma utilize its extensive RADR® data points and collaborate effectively with research partners like the National Cancer Institute. This partnership is expected to accelerate the pace of drug discovery by providing a user-friendly and secure research platform.
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, announced it will hold a conference call on November 1, 2021, at 4:30 p.m. ET to discuss its third quarter 2021 financial and operating results. This conference aims to provide insights into the company's performance and upcoming milestones. Led by CEO Panna Sharma, the management team will also highlight the use of its RADR® A.I. platform for oncology drug discovery. Interested parties can register for the event via the company's website.
Lantern Pharma (LTRN), a clinical-stage biopharmaceutical company, announced its invitation to present at the Fall Harvest - Best Ideas from the Buy-Side conference, scheduled for October 5-8, 2021. CEO Panna Sharma will present on October 6 at 10:00 AM ET. The live webcast will be available for replay after the event. Lantern Pharma leverages its RADR A.I. platform to enhance oncology drug discovery, currently developing four drug candidates across eight tumor targets. Investors can register for the conference and schedule one-on-one meetings.
Lantern Pharma (LTRN) announced a strategic collaboration with Deep Lens, aimed at accelerating patient enrollment for its Phase 2 clinical trial of LP-300 in never-smokers with non-small cell lung cancer (NSCLC). This partnership integrates Deep Lens' VIPER AI platform, enhancing patient matching to clinical trials. Lantern's RADR® AI technology will help identify biomarker signatures for effective oncological therapies. The goal is to streamline the complex drug development process, reduce costs, and improve access to treatments for cancer patients, particularly in the underserved demographic of never-smokers.
Lantern Pharma (NASDAQ: LTRN) announced that President & CEO Panna Sharma will present at the Benzinga Healthcare Small Cap Conference virtually from September 29-30, 2021. Sharma's presentation is scheduled for September 29 at 11:55 AM ET, with one-on-one meetings available throughout the event. Lantern Pharma is focused on oncology drug development, utilizing its proprietary RADR® A.I. platform to identify patients likely to benefit from their genomically targeted therapeutics.
Lantern Pharma (NASDAQ: LTRN) announced participation in two virtual investor conferences in September 2021. Panna Sharma, President & CEO, will host one-on-one meetings at the Colliers Institutional Investor Conference on September 9-10. Additionally, he will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, with a presentation available on-demand starting September 13 at 7:00 AM ET. Lantern Pharma leverages its RADR® A.I. platform to discover targeted therapies for oncology, complimented by four drug candidates in development.
Lantern Pharma (NASDAQ: LTRN) announced key additions to its leadership team to strengthen its clinical and manufacturing operations. Dr. Harry Kochat takes on the role of Senior Director of Chemistry, Manufacturing and Controls, bringing over 30 years of experience in drug development and quality control. Darlene Bunpian joins as Clinical Trial Project Manager, overseeing the planned Phase 2 trial of LP-300 in Non-Small Cell Lung Cancer. The company aims to advance its oncology drug development utilizing its RADR® A.I. platform, while the new appointments are expected to enhance operational capabilities.
Lantern Pharma (LTRN) announced positive preclinical results for its drug candidate LP-184 against glioblastoma (GBM). The study showed LP-184 inhibits tumor growth by over 106% and extends survival in mice by 27% compared to controls. Conducted with Johns Hopkins, the findings support LP-184's potential in treating GBM, particularly in patients unresponsive to standard therapies. Lantern plans to refine dosing regimens and strengthen its FDA orphan drug application. This signifies a step towards addressing critical gaps in GBM treatment, benefiting patients with varying tumor profiles.